Patents by Inventor Alan Rapraeger

Alan Rapraeger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Syndecan peptides and polypeptides as inhibitors of vascular endothelial growth factor receptor-2 (VEGFR2) and very late antigen-4 (VLA-4)
    Patent number: 10485849
    Abstract: Peptides from syndecan 1 and methods of use therefor are described. These peptides can inhibit very late antigen-4 (VLA-4) interaction with vascular endothelial growth factor-2 (VEGFR2), thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 26, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan Rapraeger, Oisun Jung
  • Syndecan peptides and polypeptides and uses thereof
    Patent number: 10080777
    Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion, or inhibiting scarring and/or pathologic neovascularization.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: September 25, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Alan Rapraeger
  • Syndecan peptides and polypeptides and uses thereof
    Patent number: 10010581
    Abstract: The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit ?4?6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion. The peptides can further be used to inhibit scarring and/or to inhibit pathologic neovascularization in a subject.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: July 3, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Alan Rapraeger
  • SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 (VEGFR2) AND VERY LATE ANTIGEN-4 (VLA-4)
    Publication number: 20180169185
    Abstract: The disclosure provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit VLA-4 interaction with VEGFR2, thereby preventing tumor cell growth and tissue invasion.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 21, 2018
    Inventors: Alan RAPRAEGER, Oisun JUNG
  • Syndecan peptides and polypeptides as inhibitors of vascular endothelial growth factor receptor-2 (VEGFR2) and very late antigen-4 (VLA-4)
    Patent number: 9878007
    Abstract: Peptides derived from amino acid residues 210 to 240 of human syndecan 1 and methods of use of such peptides are described. These peptides can inhibit activation of ?4?1 integrin (also known as very late antigen-4, VLA-4), and can inhibit engagement of VLA-4 with vascular endothelial growth factor receptor-2 (VEGFR2), thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: January 30, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan Rapraeger, Oisun Jung
  • Syndecan Peptides and Polypeptides and Uses Thereof
    Publication number: 20170087210
    Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion, or inhibiting scarring and/or pathologic neovascularization.
    Type: Application
    Filed: December 12, 2016
    Publication date: March 30, 2017
    Inventor: Alan Rapraeger
  • Syndecan Peptides and Polypeptides and Uses Thereof
    Publication number: 20170049852
    Abstract: The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit ?4?6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion. The peptides can further be used to inhibit scarring and/or to inhibit pathologic neovascularization in a subject.
    Type: Application
    Filed: October 18, 2016
    Publication date: February 23, 2017
    Inventor: Alan Rapraeger
  • Syndecan peptides and polypeptides as inhibitors of cancer
    Patent number: 9550816
    Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 24, 2017
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventor: Alan Rapraeger
  • Syndecan peptides and polypeptides as inhibitors of cancer
    Patent number: 9505818
    Abstract: The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit ?4?6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: November 29, 2016
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventor: Alan Rapraeger
  • SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF VEGFR2 AND VLA-4
    Publication number: 20160256523
    Abstract: The disclosure provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit VLA-4 interaction with VEGFR2, thereby preventing tumor cell growth and tissue invasion.
    Type: Application
    Filed: February 15, 2016
    Publication date: September 8, 2016
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Alan RAPRAEGER, Oisun JUNG
  • SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF CANCER
    Publication number: 20150218237
    Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventor: Alan RAPRAEGER
  • SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF CANCER
    Publication number: 20150218241
    Abstract: The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit ?4?6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventor: Alan RAPRAEGER
  • Syndecan peptides and polypeptides as inhibitors of cancer
    Patent number: 9034827
    Abstract: The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit ?4?6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 19, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Alan Rapraeger
  • Syndecan peptides and polypeptides as inhibitors of cancer
    Patent number: 9034828
    Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 19, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Alan Rapraeger
  • SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF CANCER
    Publication number: 20140011746
    Abstract: The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit ?4?6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion.
    Type: Application
    Filed: July 8, 2013
    Publication date: January 9, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventor: Alan RAPRAEGER
  • SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF CANCER
    Publication number: 20140011747
    Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion.
    Type: Application
    Filed: July 8, 2013
    Publication date: January 9, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventor: Alan RAPRAEGER
  • Peptides of Syndecan-1 For Inhibiting Angiogenesis
    Publication number: 20080020979
    Abstract: The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.
    Type: Application
    Filed: June 8, 2007
    Publication date: January 24, 2008
    Inventors: Alan Rapraeger, DeannaLee Beauvais
  • Syndecan 1 ectodomain inhibits cancer
    Publication number: 20070054332
    Abstract: The present invention provides for the treatment of cancers, e.g., carcinomas, using the ectodomain of syndecan 1, where the ectodomain lacks heparan sulfate residues. In addition, agents that bind the ectodomain of syndecan 1 also are useful as anti-cancer therapeutics.
    Type: Application
    Filed: August 8, 2006
    Publication date: March 8, 2007
    Inventors: Alan Rapraeger, Yan Ji
  • Peptides of syndecan-1 for inhibition of cancer
    Publication number: 20060134122
    Abstract: The present invention provides a novel peptide from the extracellular domain of syndecan-1 that inhibits migration, metastasis, survival and proliferation of cancer cells.
    Type: Application
    Filed: November 30, 2005
    Publication date: June 22, 2006
    Inventors: Alan Rapraeger, DeannaLee Beauvais